<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03600636</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2018/JCG-01</org_study_id>
    <nct_id>NCT03600636</nct_id>
  </id_info>
  <brief_title>Medium-term Follow-up of Patients With Obstetric Antiphospholipid Syndrome: MRI Study of White Matter</brief_title>
  <acronym>APS Follow Up</acronym>
  <official_title>Medium-term Follow-up of Patients With Obstetric Antiphospholipid Syndrome: MRI Study of White Matter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that the white matter of patients with obstetric
      antiphospholipid syndrome deteriorates over time
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2018</start_date>
  <completion_date type="Anticipated">December 7, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean diffusivity of white matter between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>mm2/s</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fractional anisotropy of white matter between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>Value between 0-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radial diffusivity of white matter between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>mm2/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean diffusivity of white matter between controls vs subgroups with only anticardiolipin or Lupus anticoagulant and/or aβ2GP1 antiphospholipid antibodies</measure>
    <time_frame>Day 0</time_frame>
    <description>mm2/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional anisotropy of white matter between controls vs subgroups with only anticardiolipin or Lupus anticoagulant and/or aβ2GP1 antiphospholipid antibodies</measure>
    <time_frame>Day 0</time_frame>
    <description>Value between 0-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radial diffusivity of white matter between controls vs subgroups with only anticardiolipin or Lupus anticoagulant and/or aβ2GP1 antiphospholipid antibodies</measure>
    <time_frame>Day 0</time_frame>
    <description>mm2/s</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Antiphospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>antiphospholipid syndrome patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diffusion tensor imaging MRI</intervention_name>
    <description>axial diffusion weighted sequence with 32 gradient encoding directions and two values b, 0 s / mm 2 and 1000 s / mm 2.
Fluid-attenuated inversion recovery
three-dimensional axial image weighted in T1
axial echo-planar image sequence
three-dimensional pulse sequence axial flight time</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>antiphospholipid syndrome patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have given their free and informed consent and signed the consent
             form

          -  The patient must be a member or beneficiary of a health insurance plan

          -  The patient is at least 18 years old

          -  For the target population: only women included in the publication by Pereira et al
             (2016) will be included, with no obsteric history (fetal death &gt;10 weeks or 3
             unexplained consecutive losses &lt;10 weeks)

          -  For the test group: Patients must be positive for antiphospholipid antibodies based on
             results from Pereira et al (2016)

          -  For the control group. Patients must be negative for antiphospholipid antibodies
             according to results from Pereira et al (2016)

        Exclusion Criteria:

          -  The subject is participating in a category 1 interventional study, or is in a period
             of exclusion determined by a previous study

          -  The subject refuses to sign the consent

          -  It is impossible to give the subject informed information

          -  The patient is under safeguard of justice or state guardianship

          -  The patient is pregnant, parturient or breast feeding

          -  The patient is claustrophobic

          -  The patient has a metallic foreign body (e.g. pacemaker)

          -  The patient has experienced pregnancy loss linked to infectious, metabolic, anatomic
             or hormonal factors
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe Gris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Christophe Gris, MD</last_name>
    <phone>04.66.68.32.11</phone>
    <email>jean.christophe.GRIS@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>+33 (0)4.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Christophe Gris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Paul Beregi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabricio Pereira, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Pereira FR, Macri F, Jackowski MP, Kostis WJ, Gris JC, Beregi JP, Mekkaoui C. Diffusion tensor imaging in patients with obstetric antiphospholipid syndrome without neuropsychiatric symptoms. Eur Radiol. 2016 Apr;26(4):959-68. doi: 10.1007/s00330-015-3922-x. Epub 2015 Jul 23.</citation>
    <PMID>26201292</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

